Opening Bell Alert (GNPX) Is A Nasdaq Past Champ With 5 Must-Know Potential Catalysts

On tap? How about a 2X Nasdaq past champ? Opening Bell Alert (GNPX) Is A Nasdaq Past Champ With 5 Must-Know Potential Catalysts February 23rd Dear Reader, On tap? How about a 2X Nasdaq past champ? That's exactly what we've got in store for Thursday's opening bell. Back in January, I brought this clinical-stage gene therapy company to your attention only to watch it make a solid 15% (approx.) intraday move. But that wasn't the first time I alerted it. In 2020, it ran approximately 88% in under 2 months when I brought it to your attention. Now, with 5 must-see potential catalysts including a [new $3.00 analyst target,]( a recently signed exclusive license that could have the diabetes disease quaking in its boots, and a chart where its trading above 3 key lines of potential support, it needs priority placement on your watch-list once again. Drop everything and get this 2X past champ Nasdaq idea pulled up now: *Genprex, Inc. (GNPX)* Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. And right now, GNPX has several potential catalysts to immerse yourself with. Check them out: No. 1 - Dawson James Analyst Provides $3.00 Target (Major Upside Potential From Current Trading Levels) No. 2 - This Signed Exclusive License Could Be Game-Changing In The Fight Against Diabetes No. 3 - 6-Month Chart Check: Trades Above 3 Key Lines Of Potential Support No. 4 - Company Enters Into A Game-Changing License Agreement With University Of Pittsburgh No. 5 - A Low Float Could Provide Availability For Explosive Volatility But more on those in a second... GNPX - Advancing Gene Therapy In Large Indications Helping Patients With Limited Treatment Options Oncology - REQORSA® is the first systemic gene therapy in development for cancer. - Initially targeting solid tumors in lung cancers. - Clinical trials include combinations of REQORSA with AstraZeneca’s top selling drug, Tagrisso® and Merck’s top selling drug, Keytruda®. - Lung cancer kills 1.8 million people per year, more than any other type of cancer.(1) Diabetes - Gene therapy drug candidate addresses Type 1 and Type 2 diabetes. - May reduce or eliminate daily burden of checking and monitoring blood glucose levels, and eliminate the need for insulin and daily medication. - May prevent complications of long-term diabetes. - More than 537 million people with diabetes worldwide.(2) ----- ----- GNPX Technologies REQORSA® Immunogene Therapy The First Systemically Delivered Gene Therapy Used for Cancer in Humans The company's lead product candidate, REQORSA®, immunogene therapy (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC), uses the company’s unique, proprietary ONCOPREX® Nanoparticle Delivery System, which they believe is the first systemic gene therapy delivery platform used for cancer in humans. In 2020, the FDA granted Fast Track Designation for REQORSA in combination with AstraZeneca’s Tagrisso® (osimertinib) in late-stage NSCLC patients with EFGR mutations whose tumors progressed after treatment with Tagrisso. In 2021, the FDA granted Fast Track Designation for REQORSA in combination with Merck & Co’s Keytruda® (pembrolizumab) in late-stage NSCLC patients whose disease progressed after treatment with Keytruda. The company believes that REQORSA, unlike other gene therapies, which either need to be delivered directly into tumors or require cells to be removed from the body, re-engineered and then reinserted into the body, is the first systemic gene therapy used for cancer in humans. ----- GPX-002 Diabetes Gene Therapy GPX-002, a gene therapy for diabetes, is the most recent addition of the company's licensed technologies. GPX-002 was developed by researchers at the University of Pittsburgh. Diabetic mice studies have shown that GPX-002 restored normal blood glucose levels for an extended period of time, which could translate to decades in humans. This gene therapy could not only become a new treatment option for millions of diabetes patients who need insulin replacement therapy, but it holds the potential to provide long-term effectiveness, or may even be a cure, for diabetic patients. The diabetes gene therapy, GPX-002, is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas. The genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. Diabetic mice studies show that the gene therapy restored normal blood glucose levels for an extended period of time, typically around four months. The duration of restored blood glucose levels in mice could translate to decades in humans. The diabetes gene therapy was developed by Dr. George Gittes, a researcher at the Rangos Research Center at UPMC Children’s Hospital of Pittsburgh, where preclinical research is ongoing. GPX-002 has been tested in vivo in mice and nonhuman primates. Once sufficient preclinical data has been generated, they expect to begin a Phase I clinical trial in diabetic patients, which could be the first-ever gene therapy tested in humans for diabetes. ----- ONCOPREX® Nanoparticle Delivery System The oncology drug development program utilizes their unique, proprietary non-viral ONCOPREX Nanoparticle Delivery System, which they believe is the first systemic gene therapy delivery platform used for cancer in humans. This platform, originally developed through collaborative research between the University of Texas MD Anderson Cancer Center and the National Institutes of Health, has been optimized to work with their initial product candidate, REQORSA® immunogene therapy. [Company Website.]( [Company Presentation.]( ----- And right now, based on multiple potential catalysts, past champ GNPX needs to be on your radar. Check them out: No. 1 GNPX Potential Catalyst - Dawson James Analyst Provides $3.00 Target (Major Upside Potential From Current Trading Levels) On January 30th, [Dawson James Securities']( Senior Analyst, Jason Kolbert, provided some key insight into GNPX along with tagging this profile with a $3.00 target. From its 12:00PM EST valuation Wednesday, that target provides GNPX with over 80% potential upside. Check out some highlights from the report: Lead Program in Oncology: REQORSA Immunogene Therapy (GPX-001). REQORSA is a plasmid that expresses a tumor suppressor gene TUSC2, that is deleted early during lung cancer development. REQORSA appears to have a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, reestablishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. REQORSA has been shown to be complementary with targeted drugs and immunotherapies. Clinical Status: REQORSA is currently enrolling clinical patients in two trials with a third coming. The trials are initially exploring its utility in NSCLC with a range of agents – standard of care. The Acclaim-1 clinical trial is evaluating a combination of REQORSA with Tagrisso in patients with late-stage NSCLC with activating epidermal growth factor receptor mutations, whose disease progressed after treatment. The first patient was dosed in Acclaim-1 in February 2022. A second trial, Acclaim-2 (first patient doses April 2022), is using a combination of REQORSA with Merck & Co.'s Keytruda in patients with late-stage NSCLC whose disease progressed after treatment with Keytruda. The FDA has granted Fast Track Designation for both trials. Accaim-3 is exploring REQORSA with Tecentriq in ES-SCLC patients. Diabetes Program: The company has developed a gene therapy that is designed to transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system. The therapy utilizes a procedure in which an adeno-associated virus vector is endoscopically delivered to the pancreas to insert Pdx1 and MafA genes. GPX-002 for T1D uses a glucagon promoter in alpha cells. GPX003 for T2D uses an insulin promoter in beta cells. The planned phase 1 trial represents the first-ever gene therapy tested in humans for diabetes. In vivo, preclinical studies (mice), have shown that GPX-002 restored normal blood glucose levels for an extended period. Research collaborators at the University of Pittsburgh plan to present data in non-human primates highlighting the therapeutic potential of Genprex's gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) being held February 22-25 in Berlin, Germany. Valuation: We project our model out to 2033. We apply a 30% risk cut to our projected revenues in our product model in addition to our 30% risk rate applied in our Free Cash Flow to the Firm (FCFF), discounted EPS (dEPS), and Sum-of-the-Parts (SOP) models. We use a fully diluted out year share count assuming multiple raises. The result is equal-weighted and averaged and rounded to the nearest whole number to derive our 12-month projected price target of $3.00. We note that as the company established proof of concept as a result of clinical trial data, the risk rate (r) is reduced, and valuation rises. ----- No. 2 GNPX Potential Catalyst - This Signed Exclusive License Could Be Game-Changing In The Fight Against Diabetes Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh Technologies Licensed from University of Pittsburgh May Have the Potential to Provide Long-Term Efficacy and to Change the Course of this Disease for the Millions of Patients Around the World with Type 1 or Type 2 Diabetes AUSTIN, Texas, Jan. 5, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement (the Agreement) with the University of Pittsburgh (Pitt), granting Genprex a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to gene therapy for Type 2 diabetes using the genes of the Pdx1 and MafA transcription factors. The preclinical technology, GPX-003, is believed to work by rejuvenating diminished beta cells to increase insulin expression by introducing transcription factors controlled by an insulin promoter. "This marks the Company's third technology license this year supporting our diabetes program, demonstrating the continued strengthening of our intellectual property portfolio, our diabetes program, and our position as a lead innovator in emerging diabetes gene therapies," said Rodney Varner, President and Chief Executive Officer of Genprex. "We are thrilled to have secured multiple cutting edge technologies from Pitt that expand our diabetes gene therapy program and specifically target Type 1 and Type 2 diabetes." ... [Read the full article here.]( ----- No. 3 GNPX Potential Catalyst - 6-Month Chart Check: Trades Above 3 Key Lines Of Potential Support Check out GNPX's 6-month chart: As of 12:00PM EST Wednesday, GNPX was trading above 3 of the most important lines of potential support including its: - 50-Day Simple Moving Average (SMA) - 200-Day SMA - 13-Day Exponential Moving Average (EMA) If potential support continues to grow at those key levels near term, it could provide GNPX with the foundation to continue its recent green surge since the end of 2022. And with a new $3.00 analyst target and a 52-week high of $2.67, GNPX may have significant upside potential from current levels. Now, I'm not saying GNPX is surging to any of those levels this week, but the potential upside needs to be recognized. ----- No. 4 GNPX Potential Catalyst - Company Enters Into A Game-Changing License Agreement With University Of Pittsburgh Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh Technology for modulating autoimmunity expands intellectual property portfolio AUSTIN, Texas , Dec. 15, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement (the Agreement) with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene therapy. The preclinical technology transforms macrophages enabling them to reduce autoimmune activity in Type 1 diabetes and could be complementary to the Company's existing diabetes technology. ... [Read the full article here.]( ----- No. 5 GNPX Potential Catalyst - A Low Float Could Provide Availability For Explosive Volatility According to the [Yahoo Finance]( website, GNPX has a relatively low float. The website reports this profile to have approximately 47.26Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. Could positive company news early in 2023 provide a near term spark? ----- Past Champ Recap - 5 Must-See GNPX Potential Catalysts No. 1 - Dawson James Analyst Provides $3.00 Target (Major Upside Potential From Current Trading Levels) No. 2 - This Signed Exclusive License Could Be Game-Changing In The Fight Against Diabetes No. 3 - 6-Month Chart Check: Trades Above 3 Key Lines Of Potential Support No. 4 - Company Enters Into A Game-Changing License Agreement With University Of Pittsburgh No. 5 - A Low Float Could Provide Availability For Explosive Volatility ----- Coverage is officially reinitiated on GNPX. When time permits, do this: Get GNPX on your radar now. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer [Source 1]( [Source 2]( (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 1/21/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid twenty-two thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 2/11/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid forty-six thousand USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 5/5/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 6/4/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid twelve thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockNewsWire, LLC and Venado Media, LLC, StockWireNews has been hired for a one day period on 7/22/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid twenty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockNewsWire, LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 10/29/20 and ending on 10/30/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid thirty-seven thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockNewsWire, LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 12/22/20 and ending on 12/23/20 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid seventeen thousand five hundred USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between StockNewsWire, LLC and Legends Media, LLC, StockWireNews has been hired for a period beginning on 5/4/21 and ending on 5/5/21 to publicly disseminate information about (GNPX) via Website, Email and SMS. We have been paid ninety-five thousand USD via bank wire transfer. We own zero shares of (GNPX). This ninety-five thousand USD was used for past marketing on multiple company profiles. Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 1/3/23 and ending on 1/5/23 to publicly disseminate information about (GNPX) via Website, Email and SMS. SWN Media LLC was paid twenty-five thousand USD via bank wire transfer. We own zero shares of (GNPX). Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor (FI) has been hired for a period beginning on 2/22/23 and ending on 2/23/23 to publicly disseminate information about (GNPX) via Website, Email and SMS. SWN Media LLC was paid twenty-five thousand USD via bank wire transfer. We own zero shares of (GNPX). To date we have been compensated a total of three hundred and thirty-six thousand USD via bank wire transfer to disseminate information about (GNPX). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 02/22/2023 and ending on 02/23/2023 to publicly disseminate information about (GNPX:US) via digital communications. We have been paid an additional one hundred fifteen thousand dollars USD. To date we have been paid three hundred seventy five thousand dollars USD to disseminate information about (GNPX:US) via digital communications. We own zero shares of (GNPX:US). [( Fierce | 539 W Commerce St, Dallas, TX 75208 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.net